Literature DB >> 8953085

Varying dosages of rifabutin affect white blood cell and platelet counts in human immunodeficiency virus--negative patients who are receiving multidrug regimens for pulmonary Mycobacterium avium complex disease.

D E Griffith1, B A Brown, R J Wallace.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1996        PMID： 8953085     DOI： 10.1093/clinids/23.6.1321

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN： 1058-4838            Impact factor:   9.079


× No keyword cloud information.
  9 in total

1.  Tolerance and pharmacokinetic interactions of rifabutin and azithromycin.

Authors:  R Hafner; J Bethel; H C Standiford; S Follansbee; D L Cohn; R E Polk; L Mole; R Raasch; P Kumar; D Mushatt; G Drusano
Journal:  Antimicrob Agents Chemother       Date:  2001-05       Impact factor: 5.191

Review 2.  Antimicrobial susceptibility testing, drug resistance mechanisms, and therapy of infections with nontuberculous mycobacteria.

Authors:  Barbara A Brown-Elliott; Kevin A Nash; Richard J Wallace
Journal:  Clin Microbiol Rev       Date:  2012-07       Impact factor: 26.132

Review 3.  Comparative pharmacokinetics and pharmacodynamics of the rifamycin antibacterials.

Authors:  W J Burman; K Gallicano; C Peloquin
Journal:  Clin Pharmacokinet       Date:  2001       Impact factor: 6.447

Review 4.  Risk-benefit assessment of therapies for Mycobacterium avium complex infections.

Authors:  D E Griffith
Journal:  Drug Saf       Date:  1999-08       Impact factor: 5.606

5.  Macrolide/Azalide therapy for nodular/bronchiectatic mycobacterium avium complex lung disease.

Authors:  Richard J Wallace; Barbara A Brown-Elliott; Steven McNulty; Julie V Philley; Jessica Killingley; Rebecca W Wilson; Deanna S York; Sara Shepherd; David E Griffith
Journal:  Chest       Date:  2014-08       Impact factor: 9.410

6.  HIV and SIV Associated Thrombocytopenia: An Expanding Role for Platelets in the Pathogenesis of HIV.

Authors:  Kelly A Metcalf Pate; Joseph L Mankowski
Journal:  Drug Discov Today Dis Mech       Date:  2011-11-09

7.  Randomized pharmacokinetic evaluation of different rifabutin doses in African HIV- infected tuberculosis patients on lopinavir/ritonavir-based antiretroviral therapy.

Authors:  Suhashni Naiker; Cathy Connolly; Lubbe Wiesner; Tracey Kellerman; Tarylee Reddy; Anthony Harries; Helen McIlleron; Christian Lienhardt; Alexander Pym
Journal:  BMC Pharmacol Toxicol       Date:  2014-11-19       Impact factor: 2.483

8.  Pharmacokinetics and safety of rifabutin in young HIV-infected children receiving rifabutin and lopinavir/ritonavir.

Authors:  Harry Moultrie; Helen McIlleron; Shobna Sawry; Tracy Kellermann; Lubbe Wiesner; Gurpreet Kindra; Hermien Gous; Annelies Van Rie
Journal:  J Antimicrob Chemother       Date:  2014-10-03       Impact factor: 5.790

9.  US Cystic Fibrosis Foundation and European Cystic Fibrosis Society consensus recommendations for the management of non-tuberculous mycobacteria in individuals with cystic fibrosis.

Authors:  R Andres Floto; Kenneth N Olivier; Lisa Saiman; Charles L Daley; Jean-Louis Herrmann; Jerry A Nick; Peadar G Noone; Diana Bilton; Paul Corris; Ronald L Gibson; Sarah E Hempstead; Karsten Koetz; Kathryn A Sabadosa; Isabelle Sermet-Gaudelus; Alan R Smyth; Jakko van Ingen; Richard J Wallace; Kevin L Winthrop; Bruce C Marshall; Charles S Haworth
Journal:  Thorax       Date:  2016-01       Impact factor: 9.139
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.